Abstract
We investigated the role of single nucleotide polymorphisms in genes encoding for drug-metabolizing enzymes in 209 newly diagnosed multiple myeloma patients included in a clinical trial comparing single with double intensive therapy. We observed no significant association between polymorphisms in CYP3A4, CYP3A5, MDR1, GSTM1 and GSTT1 and outcome either after treatment with induction chemotherapy or after high-dose therapy.
Publication types
-
Letter
-
Research Support, Non-U.S. Gov't
MeSH terms
-
ATP Binding Cassette Transporter, Subfamily B, Member 1 / genetics*
-
Adult
-
Aged
-
Antineoplastic Agents / therapeutic use
-
Antineoplastic Agents / toxicity*
-
Cytochrome P-450 CYP3A
-
Cytochrome P-450 Enzyme System / genetics*
-
Female
-
Glutathione S-Transferase pi / genetics*
-
Glutathione Transferase / genetics*
-
Humans
-
Male
-
Middle Aged
-
Multiple Myeloma / drug therapy*
-
Multiple Myeloma / genetics*
-
Multiple Myeloma / mortality
-
Polymorphism, Genetic*
Substances
-
ATP Binding Cassette Transporter, Subfamily B, Member 1
-
Antineoplastic Agents
-
Cytochrome P-450 Enzyme System
-
CYP3A5 protein, human
-
Cytochrome P-450 CYP3A
-
CYP3A4 protein, human
-
glutathione S-transferase T1
-
GSTP1 protein, human
-
Glutathione S-Transferase pi
-
Glutathione Transferase
-
glutathione S-transferase M1